<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01659606</url>
  </required_header>
  <id_info>
    <org_study_id>12-950</org_study_id>
    <secondary_id>IRB-P00003466</secondary_id>
    <nct_id>NCT01659606</nct_id>
  </id_info>
  <brief_title>Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita</brief_title>
  <official_title>Radiation- and Alkylator-free Hematopoietic Cell Transplantation for Bone Marrow Failure Due to Dyskeratosis Congenita / Telomere Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children’s Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Children’s Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dyskeratosis congenita is a disease that affects numerous parts of the body, most typically
      causing failure of the blood system. Lung disease, liver disease and cancer are other
      frequent causes of illness and death. Bone marrow transplantation (BMT) can cure the blood
      system but can make the lung and liver disease and risk of cancer worse, because of DNA
      damaging agents such as alkylators and radiation that are typically used in the procedure.
      Based on the biology of DC, we hypothesize that it may be possible to avoid these DNA
      damaging agents in patients with DC, and still have a successful BMT. In this protocol we
      will test whether a regimen that avoids DNA alkylators and radiation can permit successful
      BMT without compromising survival in patients with DC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dyskeratosis congenita (DC) is an inherited multisystem disorder, which classically presents
      with a clinical triad of skin pigment abnormalities, nail dystrophy, and oral leukoplakia. DC
      is part of a spectrum of telomere biology disorders, which include some forms of inherited
      idiopathic aplastic anemia, myelodysplastic syndrome, and pulmonary fibrosis and the
      congenital diseases Hoyeraal-Hreidarsson syndrome and Revesz syndrome. Progressive bone
      marrow failure (BMF) occurs in more than 80% of patients under 30 years of age and is the
      primary cause of morbidity and mortality, followed by pulmonary failure and malignancies.
      Allogeneic hematopoietic cell transplantation (HCT) is curative for the hematological
      defects, but several studies have demonstrated poor outcomes in DC patients due to increased
      early and late complications. A predisposition to pulmonary failure, vascular disease and
      secondary malignancies may contribute to the high incidence of fatal complications following
      HCT in DC patients, and provides an impetus to reduce exposure to chemotherapy and
      radiotherapy in preparative regimens. Recent studies suggest that fludarabine-based
      conditioning regimens provide stable engraftment and may avoid the toxicities seen after HCT
      for DC, but studies to date are limited to case reports, retrospective studies and a single
      prospective trial. In this study, we propose to prospectively evaluate the efficacy of a
      fludarabine- and antibody-based conditioning regimen in HCT for DC patients, with the goals
      of maintaining donor hematopoiesis and transfusion independence while decreasing early and
      late complications of HCT for DC.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">December 2034</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary engraftment</measure>
    <time_frame>Up to day +100 post-BMT</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival to day+100 post-BMT</measure>
    <time_frame>Up to day+100 post-BMT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral reactivation and infection</measure>
    <time_frame>Up to day +100 post-BMT</time_frame>
    <description>Number of participants with DNA virus (cytomegalovirus, Epstein Barr virus, or adenovirus) reactivation/infection detected by PCR screening will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related adverse events as assessed by CTCAE version 4.0</measure>
    <time_frame>Up to 1 year post-BMT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary graft failure</measure>
    <time_frame>Up to 15 years post-BMT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and chronic graft-versus-host disease (GVHD)</measure>
    <time_frame>Up to 15 years post-BMT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engraftment monitoring (chimerism)</measure>
    <time_frame>Up to 15 years post-BMT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution as assessed by quantitation of lymphocyte subsets</measure>
    <time_frame>Up to 15 years post-BMT</time_frame>
    <description>Number of participants with quantitative defects in lymphocyte subset numbers following BMT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pulmonary function as assessed by pulmonary function testing</measure>
    <time_frame>Up to 15 years post-BMT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary malignancies</measure>
    <time_frame>Up to 15 years post-BMT</time_frame>
    <description>Number of patients with malignancies following BMT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term survival</measure>
    <time_frame>Up to 15 years post-BMT</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Dyskeratosis Congenita</condition>
  <condition>Hoyeraal Hreidarsson Syndrome</condition>
  <condition>Revesz Syndrome</condition>
  <condition>Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>alemtuzumab/fludarabine conditioning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>alemtuzumab/fludarabine conditioning; cyclosporins/mycophenolate mofetil GVHD prophylaxis</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>alemtuzumab</intervention_name>
    <description>Conditioning: alemtuzumab 0.2 mg/kg/dose IV x 5 doses</description>
    <arm_group_label>alemtuzumab/fludarabine conditioning</arm_group_label>
    <other_name>Campath-1H</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>fludarabine 30 mg/m2/dose IV x 6 doses</description>
    <arm_group_label>alemtuzumab/fludarabine conditioning</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporins</intervention_name>
    <arm_group_label>alemtuzumab/fludarabine conditioning</arm_group_label>
    <other_name>cyclosporine A</other_name>
    <other_name>Neoral</other_name>
    <other_name>Sandimmune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <arm_group_label>alemtuzumab/fludarabine conditioning</arm_group_label>
    <other_name>Cellcept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Bone marrow hypocellular for age

          -  Moderate or severe aplastic anemia defined by one of the following: peripheral blood
             neutrophils &lt; 0.5 x 10^9/L; platelets &lt; 30 x 10^9/L or platelet transfusion
             dependence; reticulocytes &lt; 50 x 10^9/L in anemic patients or red cell transfusion
             dependence

          -  Diagnosis of dyskeratosis congenita based on clinical triad of abnormalities of skin
             pigmentation, nail dystrophy, oral leukoplakia; OR one of clinical triad and presence
             of two or more associated features; OR a pathogenic mutation in DKC1,TERC, TERT,
             NOP10, NHP2, TCAB1, TINF2, CTC1, PARN, RTEL1, or ACD as reported by a CLIA-approved
             laboratory; OR age-adjusted mean telomere length &lt; 1%ile in peripheral blood
             lymphocytes as reported by a CLIA-approved laboratory; OR Hoyeraal-Hreidarsson
             syndrome; OR Revesz syndrome

          -  Availability of a related or unrelated donor with a 7/8 or 8/8 match for HLA-A, B, C,
             and DRB1.

          -  Patient and/or legal guardian must be able to sign informed consent.

          -  Donor must provide a marrow allograft.

          -  Diagnosis of Fanconi anemia must be excluded by mitomycin C or diepoxybutane
             chromosomal breakage testing on peripheral blood at a CLIA-approved laboratory (not
             required for patients with a genetic mutation consistent with DC)

          -  Adequate renal function with glomerular filtration rate equal to or greater than 30
             ml/min/1.73 m2

        Exclusion Criteria:

          -  Clonal cytogenetic abnormalities associated with MDS or AML on bone marrow
             examination.

          -  Karnofsky/Lansky performance status &lt; 40.

          -  Uncontrolled bacterial, viral or fungal infections.

          -  Positive test for the human immunodeficiency virus (HIV).

          -  Pregnancy or breastfeeding.

          -  Known severe or life-threatening allergy or intolerance to fludarabine, alemtuzumab,
             cyclosporine, or mycophenolate mofetil.

          -  Positive patient anti-donor HLA antibody, which is deemed clinically significant.

          -  Prior allogeneic marrow or stem cell transplantation.

          -  Prior solid organ transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suneet Agarwal, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Children’s Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suneet Agarwal, MD, PHD</last_name>
    <phone>617-919-7579</phone>
    <email>suneet.agarwal@childrens.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Arieli</last_name>
      <phone>323-361-5744</phone>
      <email>karieli@chla.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Pulsipher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital (pediatric patients)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suneet Agarwal, MD, PHD</last_name>
      <phone>617-919-7579</phone>
      <email>suneet.agarwal@childrens.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Leslie Lehmann, MD</last_name>
      <email>leslie_lehmann@dfci.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Suneet Agarwal, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leslie Lehmann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute (adult patients)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suneet Agarwal, MD, PHD</last_name>
      <email>suneet.agarwal@childrens.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Joseph Antin, MD</last_name>
      <email>Joseph_Antin@dfci.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Suneet Agarwal, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph Antin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farid Boulad, MD</last_name>
      <phone>212-639-6684</phone>
      <email>bouladf@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Farid Boulad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kasiani Myers, MD</last_name>
      <email>Kasiani.Myers@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Kasiani Myers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barb McGlynn</last_name>
      <phone>215-590-1303</phone>
      <email>MCGLYNN@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Tim Olson, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ghadir Sasa, MD</last_name>
      <phone>832-824-4524</phone>
      <email>gssasa@txch.org</email>
    </contact>
    <investigator>
      <last_name>Ghadir Sasa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauri Burroughs, MD</last_name>
      <phone>206-667-2396</phone>
      <email>lburroug@fhcrc.org</email>
    </contact>
    <investigator>
      <last_name>Lauri Burroughs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics, American Family Children's Hospital</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Weiland</last_name>
      <phone>608-890-8070</phone>
      <email>jlweiland@pediatrics.wisc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Peds Hem Onc Main Office</last_name>
      <phone>608-263-6200</phone>
      <email>PedsHemOncResearch@lists.wisc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Inga Hoffman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2012</study_first_submitted>
  <study_first_submitted_qc>August 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2012</study_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children’s Hospital</investigator_affiliation>
    <investigator_full_name>Suneet Agarwal</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>dyskeratosis congenita</keyword>
  <keyword>bone marrow failure</keyword>
  <keyword>aplastic anemia</keyword>
  <keyword>bone marrow transplantation</keyword>
  <keyword>reduced intensity conditioning</keyword>
  <keyword>campath</keyword>
  <keyword>fludarabine</keyword>
  <keyword>telomere</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Dyskeratosis Congenita</mesh_term>
    <mesh_term>Fetal Growth Retardation</mesh_term>
    <mesh_term>Intellectual Disability</mesh_term>
    <mesh_term>Microcephaly</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Alkylating Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

